Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01811472 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01811472 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT01811472, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
Interventions
- DRUG placebo
- DRUG LCQ908
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01811472
The ClinicalTrials.gov registry entry for NCT01811472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01811472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01811472 about?
NCT01811472 is a clinical study titled "Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients". The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
What is the current status of trial NCT01811472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2013-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01811472?
The interventions under investigation include: placebo (DRUG), LCQ908 (DRUG).
Who is sponsoring clinical trial NCT01811472?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.